Skip to main content
. 2021 Oct 15;12(2):708–722. doi: 10.1016/j.apsb.2021.10.005

Figure 5.

Figure 5

Protective effects of SFN against AGE-induced ferroptosis in ECTs are AMPK-dependent. (A) and (B) Effect of sulforaphane (SFN, added 2 h before AGE treatment) on the expression of p-AMPK and AMPK, assessed using Western blotting (n = 4 per group). (C) and (D) Effect of SFN and compound C (added 2 h before AGE treatment) on the expression of p-AMPK and AMPK, assessed using Western blotting (n = 4 per group). (E) and (F) Effect of SFN and compound C (added 2 h before AGE treatment) on the expression of NRF2, assessed using Western blotting (n = 4 per group). (G) Effect of SFN and compound C (added 2 h before AGE treatment) on the level of lipid peroxidation, assessed by changes in MDA levels (n = 3–4 per group). (H) Effect of SFN and compound C (added 2 h before AGE treatment) on the expression of Ptgs2, assessed using RT-qPCR (n = 3–4 per group). Data are presented as the normalized mean ± SD (to control) or mean ± SD. AGEs, advanced glycation end-products; ECT, engineered cardiac tissue; MDA, malondialdehyde.